RVMDW
Revolution Medicines, Inc. Warrant
NASDAQ · Healthcare · Biotechnology · US
$11.89
−0.79%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
Market Cap
$2.26B
MomentumView details →
1D Return
−0.79%
YTD Return
+1149.07%
RSI (14)
54.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
Market Cap
$2.26B
RSI (14)
54.3
MomentumView details →
1D Return
−0.79%
YTD Return
+1149.07%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company focuses on developing novel targeted therapies specifically designed to treat RAS-addicted cancers, a historically challenging area in oncology that represents a significant unmet medical need. Since its inception, Revolution Medicines has built a comprehensive pipeline of investigational drugs targeting various RAS mutations, positioning itself as a specialized player in the precision oncology space.
Similar companies
Latest newsMore news →
Revolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.2d agoRevolution Medicines, Inc. signed four lease agreements for buildings at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, with staggered commencements from September 26, 2027 to September 1, 2028 and initial terms ending September 2042, subject to Phase II Closing by the landlords' acquisition of the properties.3d agoRevolution Medicines' drug daraxonrasib (brand name Rasonque) was approved by the FDA this week for treating pancreatic cancer with a key mutation.7d ago